Core Viewpoint - Aosaikang (002755.SZ) has received approval from the National Medical Products Administration for the injection of Delafloxacin mesylate, which is considered equivalent to passing the consistency evaluation, enhancing its competitive edge in the anti-infection treatment market [1] Group 1: Product Approval - Aosaikang's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Delafloxacin mesylate [1] - The approval will enrich the company's product portfolio in the anti-infection treatment area [1] Group 2: Market Impact - The exclusive approval for injectable Delafloxacin mesylate will create a differentiated competitive advantage in indications such as ABSSSI (Acute Bacterial Skin and Skin Structure Infections) and CABP (Community-Acquired Bacterial Pneumonia) [1] - This new treatment option will provide solutions for clinical multi-drug resistant bacterial infections, positively impacting the company's future operations [1]

Core Viewpoint - Aosaikang (002755.SZ) has received approval from the National Medical Products Administration for the registration of injectable Delafloxacin Mesylate, marking a significant advancement in its product portfolio [1] Group 1: Product Approval - Aosaikang's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for injectable Delafloxacin Mesylate from the National Medical Products Administration [1] Group 2: Product Characteristics - Delafloxacin is a novel broad-spectrum antibiotic that exhibits strong antibacterial activity against both Gram-positive (G+) and Gram-negative (G-) bacteria, as well as anaerobic bacteria [1] - Compared to other fluoroquinolone antibiotics, Delafloxacin has anionic properties that enhance its antibacterial activity in acidic environments, with drug accumulation levels reaching up to ten times that of other fluoroquinolones in such conditions [1] - The drug demonstrates superior antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens, distinguishing it from traditional fluoroquinolones that are not recommended for MRSA infections [1] Group 3: Clinical Validation - Delafloxacin's clinical efficacy and safety have been validated through domestic and international clinical research practices, making it the only fluoroquinolone recommended by the American Surgical Infection Society (SIS) for the treatment of MRSA in its guidelines for managing complicated skin and soft tissue infections [1] - The safety profile of Delafloxacin is favorable, with no reported cases of QT interval prolongation or phototoxicity, which are common risks associated with traditional fluoroquinolone antibiotics [1]

Core Viewpoint - Aosaikang's subsidiary has received approval for the injection of Delafloxacin Mesylate, marking it as the only product of its kind approved for sale in China, addressing a gap in the domestic market [1] Group 1: Product Approval and Market Impact - The approved drug is indicated for the treatment of acute bacterial skin and skin structure infections as well as community-acquired bacterial pneumonia [1] - Delafloxacin is noted for its strong antibacterial activity, low resistance potential, and good safety profile [1] - The approval is expected to enhance the company's anti-infection product portfolio and positively impact its operations [1] Group 2: Market Potential - The sales revenue for quinolone antibiotics is projected to reach approximately 4.9 billion yuan in 2024, indicating significant market potential [1] - The introduction of this product will fill a void in the domestic market, suggesting a strategic advantage for the company [1] - However, the sales performance of the product remains uncertain [1]